Ribociclib (Kisqali)


Indications for Prior Authorization:

  • Indicated in combination with an aromatase inhibitor [i.e., letrozole, exemestane, anastrozole] as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.

Patients must meet the following criteria for the indication(s) above:

  • Prescribed by an oncologist, AND
  • Diagnosis of recurrent or metastatic HR+, HER2- breast cancer, AND
  • Will be used in combination with letrozole, AND
  • Patient is female and postmenopausal


  • 600 mg (three 200 mg tablets) once daily for 21 consecutive days followed by 7 days off to comprise a 28-day cycle
  • Taken with an aromatase inhibitor given continuously throughout the 28-day cycle
  • Dose interruption, reduction, and/or discontinuation may be required based on individual safety and tolerability
  • Dose adjustment for use with strong CYP3A inhibitors and in patients with moderate-severe hepatic impairment: 400 mg once daily


  • 1 year

Last review date: June 12, 2017

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar